Pegylated recombinant human Factor IX: Phase I data

The open-label, dose-escalation, international Phase I NN7999-3639 trial in patients with hemophilia B showed that single doses of 25, 50 and 100 U/kg IV PEG-rFIX were well tolerated, with a half-life...